Table 1.
Clinical information of ccRCC patients
| Characteristic | Low expression of CX3CL1 | High expression of CX3CL1 | P value |
|---|---|---|---|
| n | 269 | 270 | |
| T stage, n (%) | < 0.001 | ||
| T1 | 113 (21%) | 165 (30.6%) | |
| T2 | 39 (7.2%) | 32 (5.9%) | |
| T3 | 107 (19.9%) | 72 (13.4%) | |
| T4 | 10 (1.9%) | 1 (0.2%) | |
| N stage, n (%) | 0.132 | ||
| N0 | 126 (49%) | 115 (44.7%) | |
| N1 | 12 (4.7%) | 4 (1.6%) | |
| M stage, n (%) | 0.042 | ||
| M0 | 212 (41.9%) | 216 (42.7%) | |
| M1 | 49 (9.7%) | 29 (5.7%) | |
| Pathologic stage, n (%) | < 0.001 | ||
| Stage I | 110 (20.5%) | 162 (30.2%) | |
| Stage II | 31 (5.8%) | 28 (5.2%) | |
| Stage III | 74 (13.8%) | 49 (9.1%) | |
| Stage IV | 52 (9.7%) | 30 (5.6%) | |
| Primary therapy outcome, n (%) | 0.010 | ||
| PD | 8 (5.4%) | 3 (2%) | |
| SD | 0 (0%) | 6 (4.1%) | |
| PR | 0 (0%) | 2 (1.4%) | |
| CR | 49 (33.3%) | 79 (53.7%) | |
| Histologic grade, n (%) | < 0.001 | ||
| G1 | 1 (0.2%) | 13 (2.4%) | |
| G2 | 94 (17.7%) | 141 (26.6%) | |
| G3 | 116 (21.8%) | 91 (17.1%) | |
| G4 | 52 (9.8%) | 23 (4.3%) | |
| Hemoglobin, n (%) | 0.002 | ||
| Elevated | 1 (0.2%) | 4 (0.9%) | |
| Low | 152 (33.1%) | 111 (24.2%) | |
| Normal | 82 (17.9%) | 109 (23.7%) |